Independent Modulation of Engagement and Connectivity of the Facial Network During Affect Processing by CACNA1C and ANK3 Risk Genes for Bipolar Disorder

Danai Dima, PhD; Jigar Jogia, PhD; David Collier, PhD; Evangelos Vassos, MD, PhD; Katherine E. Burdick, PhD; Sophia Frangou, MD, PhD

Bipolar disorder (BD) is characterized by mood dysregulation and a typically remitting-relapsing course.1 Genome-wide association studies (GWASs) have successfully identified several common risk-conferring variants, including markers within the CACNA1C (HGNC 1390) and ANK3 (HGNC 494) genes.2,3

The CACNA1C gene encodes the alpha subunit of the L-type voltage-dependent calcium (Ca2+) channel Cav1.2. These channels mediate the influx of Ca2+ on membrane polarization, thus influencing neuronal ability to generate and transmit electrical signals.4 In addition, the L-type Ca2+ channel subunit Cav1.2 contributes to the development and maturation of parvalbumin (PV) γ-aminobutyric acid–transmitting (GABAergic) interneurons.5 The ANK3 gene encodes ankyrin G, a cytoskeletal scaffolding protein located in the axon initial segment of neurons and in the nodes of Ranvier.6 Ankyrin G determines action potential generation by the cooperative activation of sodium gated channels at the nodes of Ranvier7 and promotes the formation of GABAergic synapses at the axon initial segment.8 Of particular interest from the perspective of the neural systems is the link between CACNA1C and ANK3 and the GABAergic interneurons. Brain oscillatory activity, considered a hallmark of neuronal network function,9 crucially depends on GABAergic function.10 Thus, CACNA1C and ANK3 may independently influence neuronal firing and coupling.

Functional magnetic resonance imaging (fMRI) studies have begun to uncover the effects of risk variants in CACNA1C and ANK3 at the neural system level in healthy individuals. Research to date has focused on GWAS-supported single-nucleotide polymorphisms at CACNA1C rs1006737 (signal maxi-
mum at rs1006737; \(P = 7.0 \times 10^{-9}\) and ANK3 rs10994336 (signal maximum at rs10994336; \(P = 9.1 \times 10^{-9}\)). Although intronic, these single-nucleotide polymorphisms are associated with altered gene expression in the brain.\(^{11,12}\) The CACNA1C rs1006737 risk allele has been associated with overactivation of the amygdala (AMG)–hippocampal complex and the prefrontal cortex during cognitive and affect-processing tasks.\(^{13,14,15}\) In addition, the CACNA1C rs1006737 risk allele influences connectivity between the right and left hippocampus\(^{16}\) and between the prefrontal cortex and the AMG\(^{17}\) and subcortical regions.\(^{18}\) Genetic variation in ANK3 may also influence prefrontal function\(^{19}\) and occipital–prefrontal coupling.\(^{20}\) These functional changes in the brain may underpin the association between either risk allele and increased behavioral reactivity to negative affective stimuli.\(^{21}\) Therefore, CACNA1C and ANK3 risk alleles may be relevant to reports of disease-associated dysregulation in engagement and connectivity between prefrontal regions with limbic\(^{22}\)–30 and occipital areas.\(^{21}\)

In this study, we combined conventional Statistical Parameter Mapping (SPM) and dynamic causal modeling (DCM)\(^{32}\) of fMRI data to define the functional consequences in the brain of CACNA1C rs1006737 and ANK3 rs10994336 during affect processing in euthymic patients with BD compared with healthy individuals. Facial affect is processed mainly in a right-sided network that involves occipital and temporal regions of the ventral visual pathway within the inferior occipital gyrus (IOG), fusiform gyrus (FG), AMG, and ventral prefrontal cortex (VPFC).\(^{33,35}\) We focused on this network primarily because it overlaps with regions implicated in BD.\(^{36}\) Moreover, initial reports have confirmed that at least 1 of the risk alleles of interest, CACNA1C rs1006737, is functional within this network; in patients with BD, the presence of this risk allele amplifies frontolimbic abnormalities during facial affect processing.\(^{15,18}\)

Based on this evidence, we tested the hypothesis that during facial affect processing, CACNA1C rs1006737 and ANK3 rs10994336 risk variants will independently act to increase disease-related abnormalities in activation and effective connectivity within the facial affect-processing network. Specifically, we hypothesized that in patients with BD, the presence of either risk allele will increase neural responses in posterior facial affect–processing network regions while exacerbating abnormalities in activation and connectivity in ventral prefrontal regions.

**Methods**

**Participants**

Eighty-seven participants of self-reported white British ancestry were identified through departmental databases as part of ongoing studies on the pathophysiology of BD. Details of the sample assessment are provided in the online material (Supplement [eMethods]). Forty-one euthymic patients with bipolar I disorder, diagnosed according to DSM-IV criteria,\(^{1}\) were included in the study. Forty-six healthy individuals without a personal or a family history of Axis I DSM-IV disorders and matched to the patients on age, sex, and IQ (measured using the Wechsler Adult Intelligence Scale–Revised\(^{37}\)) were selected as a control group. All participants underwent screening to exclude past, present, and hereditary medical disorders; DSM-IV lifetime alcohol or other drug dependence; alcohol or other drug abuse in the preceding 6 months; and contraindications to MRI. Psychopathology was assessed using the Hamilton Depression Rating Scale,\(^{38}\) the Young Mania Rating Scale,\(^{39}\) and the Brief Psychiatric Rating Scale (BPRS).\(^{40}\)

The study was approved by the Joint South London and Maudsley and Institute of Psychiatry research ethics committee. All participants provided written informed consent before study participation.

**DNA Extraction and Genotyping**

We obtained DNA from the participants using buccal swabs and conventional procedures. The CACNA1C (rs1006737; risk allele A) and ANK3 (rs10994336; risk allele T) genotypes were determined by an allelic discrimination assay (TaqMan Assay C_31344821_10; Applied Biosystems). End-point analysis was performed using fast real-time polymerase chain reaction analysis (7900HT; Applied Biosystems). Genotypes were called with the manufacture’s software (SDS, version 2.3; Applied Biosystems), and the output was checked visually to ensure genotypes fell into distinct clusters. The call rate was 100% because buccal swabs were repeated for 7 individuals for whom initial genotyping results were undetermined. Accuracy was assessed by duplicating 15% of the sample, and reproducibility was 100%.

**Facial Affect Paradigm**

The paradigm included 3 negative facial emotions (fear, anger, and sadness) in 3 separate experiments conducted in a single acquisition session in a randomized order. This paradigm consisted of 3 event-related tasks lasting 5 minutes each. In each task, 10 different facial identities (http://paulekman.com/) depicting 150% intensity of a negative (fear, anger, or sadness) or a neutral facial expression were presented in a pseudorandom order interspersed with a fixation cross. The 150% level of intensity was chosen to minimize ambiguity about the nature of the stimuli. The stimuli (affective and neutral faces and the fixation cross) were each displayed for 2 seconds and repeated 20 times. The interstimulus interval followed a Poisson distribution and varied between 3 and 9 (mean interval, 5) seconds. Participants were instructed to press the right or the left button with their dominant hand on an MRI-compatible response box to indicate whether the face had an emotional or a neutral expression. Response time and accuracy data were collected.

**Image Acquisition**

Anatomical and functional imaging data were acquired during the same session using a 1.5-T MRI system (GE Sigma; General Electric). Gradient-echo planar magnetic resonance (MR) images were acquired at each of the 16 noncontiguous planes parallel to the intercommissural (anterior commissure–posterior commissure) plane. We acquired T2*-weighted MR images reporting blood oxygenation level–dependent contrast (repetition time, 2000 milliseconds; echo time, 40 milliseconds; flip angle, 70°; section thickness, 7 mm; section skip,
For each participant, 450 fMRIs were acquired. A high-resolution T1-weighted structural image was acquired in the axial plane for coregistration (inversion recovery-prepared, spoiled gradient-echo sequence; repetition time, 18 milliseconds; echo time, 5.1 milliseconds; inversion time, 450 milliseconds; flip angle, 20°; slice thickness, 1.5 mm; matrix size, 256 × 192; field of view, 240 × 180 mm; voxel dimensions, 0.9375 × 0.9375 × 1.5 mm; number of excitations, 1).

Statistical Parametric Mapping
Data analysis was implemented using SPM8 (www.fil.ion.ucl.ac.uk/spm; Wellcome Trust Centre for Neuroimaging). Preprocessing involved spatial transformations (realignment and transformation into standard stereotactic Montreal Neurological Institute space using the participants’ anatomical image) and smoothing with an isotropic gaussian kernel of 8 mm full-width half maximum. For each participant, the fMRI data from the 3 event-related tasks (fear, anger, or sadness vs neutral) were concatenated and modeled with a general linear (convolution) model. Vectors of onset representing correct responses were convolved with a canonical hemodynamic response function. Six movement parameters were also entered as nuisance covariates. The means of the 3 sessions were also modeled, as was the transition at the end of each session. For each participant, contrast images (affective > neutral facial expressions) were produced.

Group-level analyses were based on random-effects analyses of the single-subject contrast images using the summary statistic approach. Data were analyzed using 2 approaches. For each genetic variant, the primary hypothesis-testing analyses focused on the effect of the diagnosis, the genotype, and their interaction within volumes of interest (VOIs) defined within the facial affect-processing network, followed by whole-brain analyses to test for significant main effects or interactions outside the predefined areas.

Based on previous work from our laboratory,33 we selected VOIs within the IOG, FG, AMG, and VPFC, which are the key brain regions engaged in facial processing. These VOIs were defined using a mask derived from the automated anatomical labeling atlas in Wake Forest University PickAtlas (version 3.0.3; www.fmri.wfubmc.edu/software/PickAtlas).

For the VOI and whole-brain analyses, statistical inference was based on a threshold of $P < .001$, uncorrected, with a voxelwise extent threshold of $k = 20$; in addition, for the VOI analysis, a small-volume correction was applied (VOI radius, 10 [measured as percentage of change in BOLD signal]; $P < .05$ at cluster level, familywise error).42 We used response times and the BPRS total score as covariates in all analyses. The BPRS, Hamilton Depression Rating Scale, and Young Mania Rating Scale scores were highly correlated (for all, $R > 0.82$ [P > .0001]). To avoid collinearity, we used the total BPRS score as a covariate because, unlike the other scales, it is applicable to non-clinical populations. In the BPRS, symptoms are rated from 1 (absent) to 7 (extremely severe), with ratings below 4 corresponding to nonpathological experiences.

Measures of brain activation (weighted parameter estimates)42 were extracted for each VOI from 1-sample t tests (contrast images affective > neutral facial expressions) for each diagnostic group using a region-of-interest toolbox for SPM (MarsBar; http://marsbar.sourceforge.net). These measures were imported in commercially available software (SPSS, version 17; SPSS, Inc) to examine their association with task performance and with medication type and dose on the day of scanning.

Dynamic Causal Modeling
Dynamic causal modeling32 is a Bayesian model comparison procedure that estimates directed interactions within neural systems. Crucially, DCM models these neural interactions and distinguishes between endogenous and context-specific coupling while accounting for the effects of experimentally controlled network perturbations (in contrast to stimulus-locked coupling).32,43 In the previous study from our laboratory,32 the strategy for determining the most parsimonious model for facial affect processing was detailed. In summary, 4-a area DCM was defined for all participants with endogenous connections between VOIs specified in the IOG, FG, AMG, and VPFC, with the main effect of all faces as the driving input to the IOG. We then produced and tested 7 models that included all possible permutations regarding how facial affect (fear, anger, or sadness) could modulate connections within the network (Supplement [eFigure]).

Model comparison was implemented using random-effects Bayesian model selection in DCM8 to compute exceedance and posterior probabilities at the group level34 separately for controls and patients with BD. The exceedance probability of a given model denotes the probability that this model is more likely than any other model tested. To produce quantitative measures of the strength of effective connectivity and its modulation, we used random-effects Bayesian model averaging to obtain mean connectivity estimates (weighted by their posterior model probability) across all models and all subjects.45 Once the optimal models for controls and patients were determined, we tested the modulation of the model connections by each of the risk variants separately in SPSS, version 17, using 2-sample t tests or nonparametric tests when data were not normally distributed based on the Kolmogorov-Smirnov criterion, with $a = .05$.

Results
Participants
Demographic and Clinical Data
Results for the CACNA1C rs1006737 (risk allele A) are shown in Table 1. Individuals with the CACNA1C AA allele (5 patients with BD and 4 controls) were considered together with AG heterozygotes (19 patients with BD and 17 controls) within each diagnostic group. We found no effect of either genotype or of the genotype × diagnosis interaction.
Table 1. Demographic and Clinical Characteristics of the Study Participants by Diagnosis, CACNA1C Genotype (rs1006737; Risk Allele A), and Diagnosis × Genotype Interaction

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Effect of Diagnosis</th>
<th>Effect of CACNA1C Genotype</th>
<th>Diagnosis × Genotype Interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BD Patients (n = 41)</td>
<td>Controls (n = 46)</td>
<td>AA+AG (n = 42)</td>
</tr>
<tr>
<td>Age, y</td>
<td>44.3 (11.9)</td>
<td>40.3 (13.2)</td>
<td>40.1 (11.1)</td>
</tr>
<tr>
<td>Sex, No. of participants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>20</td>
<td>25</td>
<td>21</td>
</tr>
<tr>
<td>Female</td>
<td>21</td>
<td>21</td>
<td>21</td>
</tr>
<tr>
<td>Educational level</td>
<td>3.5 (1.0)</td>
<td>3.6 (1.0)</td>
<td>3.8 (0.9)</td>
</tr>
<tr>
<td>IQ</td>
<td>117.9 (17.9)</td>
<td>112.6 (14.5)</td>
<td>113.6 (18.4)</td>
</tr>
<tr>
<td>HDRS total scoreab,c</td>
<td>4.8 (5.3)</td>
<td>0.1 (0.5)</td>
<td>2.0 (3.5)</td>
</tr>
<tr>
<td>YMRS total scoreab,c</td>
<td>1.4 (3.0)</td>
<td>0.2 (0.6)</td>
<td>0.3 (0.7)</td>
</tr>
<tr>
<td>BPRS total scoreab,c</td>
<td>27.5 (4.0)</td>
<td>24.3 (0.7)</td>
<td>25.4 (2.1)</td>
</tr>
<tr>
<td>Age at onset, y</td>
<td>24.7 (8.0)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Duration of illness, y</td>
<td>20.2 (10.5)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>No. of depressive episodes</td>
<td>5.7 (7.5)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>No. of manic episodes</td>
<td>5.6 (7.7)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Correctly identified faces, %</td>
<td>90.3 (4.1)</td>
<td>93.1 (4.8)</td>
<td>91.7 (7.7)</td>
</tr>
<tr>
<td>Response time, msab</td>
<td>1491 (209)</td>
<td>1109 (241)</td>
<td>1189 (267)</td>
</tr>
</tbody>
</table>

Abbreviations: BD, bipolar disorder; BPRS, Brief Psychiatric Rating Scale; ellipses, not applicable; HDRS, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale.

a Unless otherwise indicated, data are expressed as mean (SD).
b Scores for BD patients are significantly greater than those for controls (P < .02).
c Scores for BD patients in the AA+AG group are significantly greater than those for all other groups (P < .03).

Table 2. Demographic and Clinical Characteristics of the Study Participants by Diagnosis, ANK3 Genotype (rs10994336; Risk Allele T), and Diagnosis × Genotype Interaction

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Effect of Diagnosis</th>
<th>Effect of ANK3 Genotype</th>
<th>Diagnosis × Genotype Interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BD Patients (n = 41)</td>
<td>Controls (n = 46)</td>
<td>TT+CT (n = 30)</td>
</tr>
<tr>
<td>Age, y</td>
<td>44.3 (11.9)</td>
<td>40.3 (13.2)</td>
<td>42.3 (13.0)</td>
</tr>
<tr>
<td>Sex, No. of participants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>20</td>
<td>25</td>
<td>17</td>
</tr>
<tr>
<td>Female</td>
<td>21</td>
<td>21</td>
<td>13</td>
</tr>
<tr>
<td>Educational level</td>
<td>3.5 (1.0)</td>
<td>3.6 (1.0)</td>
<td>3.5 (1.0)</td>
</tr>
<tr>
<td>IQ</td>
<td>117.9 (17.9)</td>
<td>112.6 (14.5)</td>
<td>121.7 (16.3)</td>
</tr>
<tr>
<td>HDRS total scoreab,c</td>
<td>4.8 (5.3)</td>
<td>0.1 (0.5)</td>
<td>2.9 (4.8)</td>
</tr>
<tr>
<td>YMRS total scoreab,c</td>
<td>1.4 (3.0)</td>
<td>0.2 (0.6)</td>
<td>0.8 (2.2)</td>
</tr>
<tr>
<td>BPRS total scoreab,c</td>
<td>27.5 (4.0)</td>
<td>24.3 (0.7)</td>
<td>26.2 (3.7)</td>
</tr>
<tr>
<td>Age at onset, y</td>
<td>24.7 (8.0)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Duration of illness, y</td>
<td>20.2 (10.5)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>No. of depressive episodes</td>
<td>5.7 (7.5)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>No. of manic episodes</td>
<td>5.6 (7.7)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>Correctly identified faces, %</td>
<td>90.3 (4.1)</td>
<td>93.1 (4.8)</td>
<td>92.7 (5.9)</td>
</tr>
<tr>
<td>Response time, msab</td>
<td>1491 (209)</td>
<td>1109 (241)</td>
<td>1223 (260)</td>
</tr>
</tbody>
</table>

Abbreviations: BD, bipolar disorder; BPRS, Brief Psychiatric Rating Scale; ellipses, not applicable; HDRS, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale.

a Scores for BD patients are significantly greater than those for controls (P < .02).
b Scores for BD patients in the CT+TT group are significantly greater than those for all other groups (P < .02).
interaction on demographic data (P > .11) or on clinical variables (P > .29) except for BD carriers of the CACNA1C or ANK3 risk allele who had higher symptom scores compared with all other groups (P < .02). Similar behavioral changes have been observed in healthy carriers of either risk allele who report higher ratings of anxiety, anhedonia, and neuroticism.16,21

**Task Performance**
Details are shown in Tables 1 and 2. No significant effect of diagnosis, genotype, or their interaction was observed for accuracy (P > .63). Patients had longer mean response times compared with the controls, but no effect of genotype or of a genotype × diagnosis interaction was detected (P > .56).

**Statistical Parametric Mapping**
Processing of affective compared with neutral facial expressions was associated with enhanced activation throughout the relevant network in both diagnostic groups (Supplement [eTable]). However, compared with controls, patients with BD (regardless of genotype) showed reduced activation in the visual cortex (IOG), temporal visual association cortex (FG), and the VPFC. The CACNA1C and ANK3 risk alleles were independently associated with increased activation in the IOG, FG, and AMG in all participants regardless of diagnosis (Figure 1). A significant diagnosis × genotype interaction was noted in the VPFC. The presence of either risk allele was associated with increased VPFC activation in controls but reduced VPFC activation in patients with BD (Figure 1). The main effect of genotype and the genotype × diagnosis interaction observed in the VOI analyses remained significant in the whole-brain volume analyses. The latter analyses identified further regions with significant effect of genotype in the angular gyrus (x = −30, y = −54, z = 34 [z score, 3.34]) for carriers of the CACNA1C risk allele and the middle occipital gyrus (left: x = −26, y = −90, z = −4 [z score, 3.70]; right: x = 48, y = −66, z = −14 [z score, 3.68]) for carriers of the ANK3 risk allele.

**Dynamic Causal Modeling**
Results are presented in Figure 2. For simplicity, we used a single modulatory term labeled *facial affect*. The models contain distinct modulatory inputs for fear, anger, and sadness, allowing us to test their individual influence on connectivity.

In the controls, we replicated the previous finding35 that the optimal model for facial processing with an exceedance probability of 41% contains reciprocal connections among all 4 network areas (IOG, FG, AMG, and VPFC). Affect processing (regardless of valence or genotype) was associated with significantly increased modulation of the forward connection from the IOG to the VPFC (Figure 2A and Supplement [eFigure, model 1]). In the controls, the presence of the CACNA1C (P = .02) and ANK3 (P = .04) risk alleles further increased effective connectivity between these regions (Figure 2B).

In the patients with BD, as in the controls, the optimal model with an exceedance probability of 32% also contained reciprocal connections among all 4 network areas (IOG, FG, AMG, and VPFC). Affect processing (regardless of valence or genotype) was associated with reduced visual-prefrontal connectivity coupled with increased modulation in the forward connection from the
Figure 2. Results of Dynamic Causal Modeling (DCM) and Bayesian Model Averaging in Healthy Controls and Patients With Bipolar Disorder (BD)

A, Optimal DCM selection. Models compromised by a 4-area DCM are specified with bidirectional endogenous connections among all regions (inferior occipital gyrus [IOG], fusiform gyrus [FG], amygdala [AMG], and ventral prefrontal cortex [VPFC]) and a driving input of all faces into the IOG. For ease of display, affect modulations are labeled as facial affect (black dot) but correspond to the distinct modulations of fearful, angry, and sad faces. B, Alterations in effective connectivity within the facial processing network established by Bayesian model averaging across all models considered. For controls, the bold black arrows indicate significantly increased connectivity from the IOG to the VPFC modulated by the CACNA1C (rs1006737) and ANK3 (rs10994336) risk variants. For patients with BD, the dashed arrows indicate significantly decreased connectivity from the IOG to the VPFC modulated by the CACNA1C (rs1006737) and ANK3 (rs10994336) risk variants. Black solid arrows indicate all other network connections.

AMG to the VPFC (Figure 2A and Supplement eFigure, model 3). Moreover, BD carriers of the CACNA1C (P = .02) or ANK3 (P = .04) risk variant expressed further reductions in connectivity from the IOG to the VPFC (Figure 2B).

Differences between the 2 diagnostic groups were noted in the modulation by facial affect of the IOG to VPFC (P = .02) and AMG to VPFC (P = .03) connections. Furthermore, the genotype × group interaction for the IOG to VPFC connection was statistically significant for the CACNA1C (P = .003) and ANK3 (P = .01) genotypes.

No significant effect of medication was found in any of the analyses. In addition, no significant correlation between medication dose and any brain activation or connectivity parameters (P > .42) was found.

Discussion

We used SPM and DCM to investigate the effect of CACNA1C and ANK3 GWAS-supported risk variants on regional activation and interregional connectivity during facial affect processing in healthy controls compared with euthymic patients with BD. We found that both genetic risk variants were independently associated with (1) increased engagement in the ventral visual pathway and in the AMG irrespective of diagnosis, (2) increased VPFC activation and visual-prefrontal effective connectivity in controls, and (3) increased deviance in ventral prefrontal activation and visual-prefrontal effective connectivity in patients with BD.

The Effect of CACNA1C and ANK3 Variation on the Facial Affect-Processing Network in Controls

As expected,35,46 facial affect processing enhanced regional activation within the corresponding network regardless of genotype. The presence of either risk allele amplified these affect-related neural responses. This genotype effect has been reported previously in the AMG14,15 and VPFC15 for CACNA1C rs1006737. Our study suggests that genetic modulation of regional activation by CACNA1C rs1006737 within this network is not limited to frontolimbic regions but extends to the ventral visual pathway (IOG and FG). A similar pattern of affect-related overactivation throughout the facial-processing network was also present in ANK3 rs10994336 risk allele carriers.

Regardless of genotype, optimal processing of visual stimuli depends on visual-prefrontal cortical coupling. Specifically, visual cortical areas in the IOG rapidly project parcellary pattern of affect-related overactivation throughout the visual-prefrontal activation and visual-prefrontal effective connectivity in patients with BD.
Although the underlying molecular mechanisms are beyond the resolution of neuroimaging, we hypothesize that the neurogenetic effects of either risk allele are mediated through changes in brain oscillatory activity. The functional coupling of visual and prefrontal cortices during visual processing relies on synchronized long-range oscillations within the gamma frequency band. Recent optogenetic experiments have confirmed that gamma oscillations originate from PV-GABAergic interneurons following excitatory input from pyramidal cells. The \textit{CACNA1C} and \textit{ANK3} genes are known to modulate neuronal firing, signaling, and PV-interneuron function, which are pertinent to the generation of gamma oscillations\textsuperscript{4-5,5,6} and offer a plausible link between the molecular properties of the genes and their putative system-level effects observed here.

**Effect of \textit{CACNA1C} and \textit{ANK3} Variation on the Facial Affect-Processing Network in BD**

Regardless of genotype, patients with BD showed VPFC hypoactivation, consistent with previous reports.\textsuperscript{26,27,52} This abnormality was exacerbated in BD carriers of either risk allele. In all other network regions, the presence of either risk allele amplified affect-related neural responses. This genotype-related imbalance in engagement between posterior facial network regions and the VPFC has been previously described for \textit{CACNA1C} rs1006737.\textsuperscript{15} Our findings suggest a similar effect for the \textit{ANK3} rs10994336 risk allele.

Regardless of genotype, the patients with BD showed evidence of significant reduction in visual-prefrontal cortical effective connectivity but increased forward connectivity between the AMG and VPFC compared with the controls. These findings confirm previous reports of increased AMG-prefrontal coupling in BD\textsuperscript{29-30} and provide new evidence of visual-prefrontal reduction in effective coupling. The latter was affected by \textit{CACNA1C} and \textit{ANK3} variation because BD carriers of either risk allele show greater dysfunction. Several reports have found abnormal neuronal synchronization in BD in the long-range gamma band during multiple tasks,\textsuperscript{53-55} including facial affect processing,\textsuperscript{56} that provides a plausible mechanistic explanation for the observed reduction in visual-prefrontal cortical connectivity in BD.

**Central Role of VPFC Dysfunction in the Pathophysiology of BD**

Our results also strengthen the case for VPFC pathology in the pathogenesis of BD.\textsuperscript{57} Postmortem studies in BD report neuropathological abnormalities in the VPFC, leading to regional reductions in the number and density of pyramidal cells and PV interneurons.\textsuperscript{58-59} The mechanisms involved are not established, but multiple lines of evidence implicates reduced expression of neurotrophins,\textsuperscript{60,61} abnormalities in oxidative energy generation,\textsuperscript{56,61} and mitochondrial dysfunction resulting in altered Ca\textsuperscript{2+} regulation\textsuperscript{60} and PV-interneuron reduction.\textsuperscript{62} Given the known properties of the \textit{CACNA1C} and \textit{ANK3} risk alleles discussed here, we postulate that the risk alleles may further reduce the integrity of the interactions between excitatory signals from pyramidal neurons and inhibition by GABAergic interneurons.\textsuperscript{10,63} A more precise formulation of a pathophysiological model for BD crucially depends on the future availability of data directly testing these predictions.

**Methodological Considerations**

Several methodological issues require further consideration. First, possible medication effects on the study results cannot be conclusively refuted. However, we found no significant relationship between medication and measures of regional activation or effective connectivity. Second, we did not test for epistatic effects because the number of individuals carrying both risk variants was small (3 patients and 3 controls). This finding is expected, given the rarity of the \textit{ANK3} risk allele. However, Moskvina and colleagues\textsuperscript{54} found no convincing evidence of epistasis between the GWAS-supported single-nucleotide polymorphisms in \textit{ANK3} and \textit{CACNA1C} in the Wellcome Trust Case Control Consortium data (1868 cases with BD and 2938 controls). They suggested that GWAS-supported loci may be detectable because they do not require interactions to exert an effect. Finally, the absence of a diagnosis or a genotype effect on task performance is a particular strength of the study and confirms the increased assay sensitivity of neuroimaging in uncovering the neural correlates of diagnostic and genetic variability. The genetic risk factors examined here and the results obtained show at least partial overlap with findings in other disorders, primarily schizophrenia.\textsuperscript{59-65} This observation adds to accumulating evidence that the diagnostic categories used in clinical practice are unlikely to represent underlying genetic and pathophysiological risk accurately.

In summary, we demonstrated that the effect of \textit{CACNA1C} rs1006737 and \textit{ANK3} rs10994336 (or genetic variants in linkage disequilibrium) on the brain converges on neural circuitry involved in facial affect processing. Thus, we provide a mechanism linking BD with genome-wide genetic risk variants.

**ARTICLE INFORMATION**

\textbf{Submitted for Publication:} September 25, 2012; final revision received January 27, 2013; accepted March 11, 2013.

\textbf{Published Online:} October 9, 2013. doi:10.1001/jamapsychiatry.2013.2099.

\textbf{Author Contributions:} Dr Frangou takes responsibility for the integrity of the data and the accuracy of the analysis.

\textbf{Study concept and design:} Collier, Frangou.

\textbf{Acquisition of data:} Vassos, Frangou.

\textbf{Analysis and interpretation of data:} All authors.

\textbf{Drafting of the manuscript:} Dima, Collier, Frangou.

\textbf{Critical revision of the manuscript for important intellectual content:} All authors.

\textbf{Statistical analysis:} Dima, Jogia, Vassos, Burdick, Frangou.

\textbf{Obtained funding:} Frangou.

\textbf{Administrative, technical, and material support:} Dima, Jogia, Collier.

\textbf{Study supervision:} Vassos, Frangou.

\textbf{Conflict of Interest Disclosures:} None reported.

\textbf{Funding/Support:} This study was supported by an Independent Investigator Award 2008 from the National Alliance for Research in Schizophrenia and Affective Disorders (Dr Frangou).

\textbf{Role of the Sponsor:} The National Alliance for Research in Schizophrenia and Affective Disorders had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

\textbf{Copyright 2013 American Medical Association. All rights reserved.}
Cis-acting genetic variation in the 3′-UTR of the CACNA1C gene influences limbic circuitry and fronto-temporal system dysregulation in bipolar disorder. Arch Gen Psychiatry. 2010;67(8):803-811.


Risk Genes for Bipolar Disorder


